Details
Stereochemistry | RACEMIC |
Molecular Formula | C11H12N2O2.ClH |
Molecular Weight | 240.686 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C1CN=C(N1)C2COC3=CC=CC=C3O2
InChI
InChIKey=MYUBYOVCLMEAOH-UHFFFAOYSA-N
InChI=1S/C11H12N2O2.ClH/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11;/h1-4,10H,5-7H2,(H,12,13);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C11H12N2O2 |
Molecular Weight | 204.2252 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Idazoxan is an alpha2 receptor antagonist which also shows activity at imidazoline I1 and I2 receptors and modulates the release of dopamine. Idazoxan was in phase II development in the US. Later the development of idazoxan for schizophrenia was discontinued. It was also in clinical trials for cognition disorders in United Kingdom, and was also discontinued. Idazoxan is used in scientific research as a tool for the study of alpha 2-adrenoceptors.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1942 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10636247 |
7.71 null [pIC50] | ||
Target ID: CHEMBL1867 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10636247 |
8.08 null [pIC50] | ||
Target ID: CHEMBL1916 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10636247 |
7.27 null [pIC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
179.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2872058/ |
0.3 mg/kg single, oral dose: 0.3 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
IDAZOXAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
560.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2872058/ |
0.3 mg/kg single, intravenous dose: 0.3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
IDAZOXAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.59 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2872058/ |
0.3 mg/kg single, oral dose: 0.3 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
IDAZOXAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2872058/ |
0.3 mg/kg single, intravenous dose: 0.3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
IDAZOXAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of the pesticide amitraz and its metabolite BTS 27271 on insulin and glucagon secretion from the perfused rat pancreas: involvement of alpha2D-adrenergic receptors. | 1999 Nov |
|
Effect of alpha-2 adrenoceptor antagonists on colonic function in rats. | 2000 Jun |
|
Hypoxic-ischaemic brain damage in immature rats: effects of adrenoceptor modulation. | 2001 |
|
Co-transmitter function of ATP in central catecholaminergic neurons of the rat. | 2001 |
|
Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. | 2001 Apr |
|
Alpha2A-adrenoceptor mediated tachypnea in awake goats. | 2001 Apr |
|
Agonist trafficking of G(i/o)-mediated alpha(2A)-adrenoceptor responses in HEL 92.1.7 cells. | 2001 Apr |
|
Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhibition in the rat forced swimming test. | 2001 Apr |
|
The noradrenaline-dopamine interaction in the rat medial prefrontal cortex studied by multi-probe microdialysis. | 2001 Apr 27 |
|
Nitric oxide-independent effects of tempol on sympathetic nerve activity and blood pressure in normotensive rats. | 2001 Aug |
|
Differential responses of regional vascular beds to local injection of agmatine in rats. | 2001 Dec |
|
In vitro and in vivo impairment of alpha2-adrenergic receptor-dependent antilipolysis by fatty acids in human adipose tissue. | 2001 Dec |
|
Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. | 2001 Dec 13 |
|
Desensitization of insulin secretory response to imidazolines, tolbutamide, and quinine. II. Electrophysiological and fluorimetric studies. | 2001 Dec 15 |
|
Desensitization of insulin secretory response to imidazolines, tolbutamide, and quinine. I. Secretory and morphological studies. | 2001 Dec 15 |
|
Presynaptic alpha2-adrenoceptor-mediated modulation of adenosine 5' triphosphate and noradrenaline corelease: differences in canine mesenteric artery and vein. | 2001 Feb |
|
Imidazolines inhibit secretory responses of rat colonic mucosa to calcium-dependent but not cyclic AMP-dependent secretagogues. | 2001 Feb |
|
Differential effects of clonidine, dopamine, dobutamine, and dopexamine on basal and acid-stimulated mucosal blood flow in the rat stomach. | 2001 Feb |
|
Rabbit alpha2-adrenoceptors: both platelets and adipocytes have alpha2A-pharmacology. | 2001 Jul |
|
Differential [(3)H]idazoxan and [(3)H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) binding to imidazoline I(2) receptors in human postmortem frontal cortex. | 2001 Jul 6 |
|
The alpha 2 adrenoceptor antagonists RX 821002 and yohimbine delay-dependently impair choice accuracy in a delayed non-matching-to-position task in rats. | 2001 Jun |
|
Agmatine inhibits carotid sinus baroreflex in anesthetized rats. | 2001 Mar |
|
Receptor phosphorylation mediates estradiol reduction of alpha2-adrenoceptor coupling to G protein in the hypothalamus of female rats. | 2001 Mar |
|
Inverse agonist activity at the alpha(2A)-adrenergic receptor. | 2001 Mar |
|
The differential effects of prenatal stress in rats on the acoustic startle reflex under baseline conditions and in response to anxiogenic drugs. | 2001 Mar 1 |
|
Posttraining infusion of norepinephrine and corticotropin releasing factor into the bed nucleus of the stria terminalis enhanced retention in an inhibitory avoidance task. | 2001 Mar 31 |
|
Morphine and clonidine activate different K+ channels on rat amygdala neurons. | 2001 Mar 9 |
|
Analysis of ligand activation of alpha 2-adrenoceptor subtypes under conditions of equal G alpha protein stoichiometry. | 2001 May |
|
Antidepressant drug-induced alterations in neuron-localized tumor necrosis factor-alpha mRNA and alpha(2)-adrenergic receptor sensitivity. | 2001 May |
|
Chronic hypoxia alters prejunctional alpha(2)-receptor function in vascular adrenergic nerves of adult and fetal sheep. | 2001 Sep |
|
Dopamine inhibits vasopressin action in the rat inner medullary collecting duct via alpha(2)-adrenoceptors. | 2001 Sep |
|
Alpha2-adrenoceptor activation increases a cationic conductance and spontaneous GABAergic synaptic activity in dopaminergic neurones of the rat substantia nigra. | 2002 |
|
Changes of the excitability of rat trigeminal root ganglion neurons evoked by alpha(2)-adrenoreceptors. | 2002 |
|
Intrathecal clonidine decreases spinal nitric oxide release in a rat model of complete Freund's adjuvant induced inflammatory pain. | 2002 Aug |
|
Effect of antisense knock-down of alpha(2a)- and alpha(2c)-adrenoceptors on the antinociceptive action of clonidine on trigeminal nociception in the rat. | 2002 Jul |
|
Involvement of imidazoline receptors in the centrally acting muscle-relaxant effects of tizanidine. | 2002 Jun 12 |
|
Spinal noradrenergic activation mediates allodynia reduction from an allosteric adenosine modulator in a rat model of neuropathic pain. | 2002 May |
|
In vivo tonic modulation of the noradrenaline release in the rat cortex by locus coeruleus somatodendritic alpha(2)-adrenoceptors. | 2002 May 10 |
|
Biochemical and functional characterization of alpha-adrenergic receptors in the rabbit vagina. | 2002 Nov 1 |
|
Central serotonergic and adrenergic/imidazoline inhibitory mechanisms on sodium and water intake. | 2002 Nov 22 |
|
RX 821002 as a tool for physiological investigation of alpha(2)-adrenoceptors. | 2002 Summer |
|
Central alpha(2) adrenergic receptors and cholinergic-induced salivation in rats. | 2003 Jan 30 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11481696
Parkinson's disease:single oral doses (10 mg, 20 mg, and 40 mg) of idazoxan
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11471213
Idazoxan (10(-4) mol/L), an alpha 2-adrenergic receptor (alpha 2-AR) and imidazoline receptor (IR) antagonist, abolished the Agm-induced vasorelaxation completely under the condition of CaCl2-induced precontraction in the isolated aortic artery of rats..
Substance Class |
Chemical
Created
by
admin
on
Edited
Sun Dec 18 01:58:14 UTC 2022
by
admin
on
Sun Dec 18 01:58:14 UTC 2022
|
Record UNII |
15394QZS7A
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
90755-83-2
Created by
admin on Sun Dec 18 01:58:15 UTC 2022 , Edited by admin on Sun Dec 18 01:58:15 UTC 2022
|
SUPERSEDED | |||
|
154494
Created by
admin on Sun Dec 18 01:58:15 UTC 2022 , Edited by admin on Sun Dec 18 01:58:15 UTC 2022
|
PRIMARY | |||
|
M6198
Created by
admin on Sun Dec 18 01:58:15 UTC 2022 , Edited by admin on Sun Dec 18 01:58:15 UTC 2022
|
PRIMARY | Merck Index | ||
|
79944-56-2
Created by
admin on Sun Dec 18 01:58:15 UTC 2022 , Edited by admin on Sun Dec 18 01:58:15 UTC 2022
|
PRIMARY | |||
|
109518-43-6
Created by
admin on Sun Dec 18 01:58:15 UTC 2022 , Edited by admin on Sun Dec 18 01:58:15 UTC 2022
|
SUPERSEDED | |||
|
15394QZS7A
Created by
admin on Sun Dec 18 01:58:15 UTC 2022 , Edited by admin on Sun Dec 18 01:58:15 UTC 2022
|
PRIMARY | |||
|
DTXSID10920189
Created by
admin on Sun Dec 18 01:58:15 UTC 2022 , Edited by admin on Sun Dec 18 01:58:15 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |